6/10/2010

Regeneron Pharmaceuticals' gout drug Arcalyst reduced flare-ups by 80% when administered at 160 milligrams once a week, according to a late-stage trial. The company is banking on the success of Arcalyst and two other experimental drugs in late-stage development to earn as much as $2 billion annually.

Related Summaries